AMPK-SP1-Guided Dynein Expression Represents a New Energy-Responsive Mechanism and Therapeutic Target for Diabetic Nephropathy.

Jillian Williquett Chantal Allamargot Hua Sun

Published in: Kidney360 (2024)

Our work implicates AMPK-SP1-regulated dynein expression as an early mechanism that translates energy disturbances in diabetes into podocyte dysfunction. Pharmaceutical restoration of dynein expression by targeting SP1 offers a new therapeutic strategy to prevent DN.

Keyphrases

diabetic nephropathy
poor prognosis
type diabetes
skeletal muscle
binding protein
oxidative stress
transcription factor
protein kinase
metabolic syndrome
drug delivery